Literature DB >> 9093260

Severe hepatitis in three AIDS patients treated with indinavir.

N Bräu, H L Leaf, R L Wieczorek, D M Margolis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093260     DOI: 10.1016/S0140-6736(05)62700-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  17 in total

Review 1.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

Review 2.  Indinavir: a review of its use in the management of HIV infection.

Authors:  G L Plosker; S Noble
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

3.  Acute hepatitis in a patient treated with saquinavir and ritonavir: absence of cross-toxicity with indinavir.

Authors:  B Vandercam; M Moreau; C Horsmans; J L Gala
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

4.  Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction.

Authors:  Min Liang; Masakazu Kamata; Kevin N Chen; Nonia Pariente; Dong Sung An; Irvin S Y Chen
Journal:  J Gene Med       Date:  2010-03       Impact factor: 4.565

5.  Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.

Authors:  M Savès; F Raffi; P Clevenbergh; B Marchou; A Waldner-Combernoux; P Morlat; V Le Moing; C Rivière; G Chêne; C Leport
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

6.  The chemical bases of the various AIDS epidemics: recreational drugs, anti-viral chemotherapy and malnutrition.

Authors:  Peter Duesberg; Claus Koehnlein; David Rasnick
Journal:  J Biosci       Date:  2003-06       Impact factor: 1.826

7.  Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.

Authors:  J Judy Chang; Fiona Wightman; Angeline Bartholomeusz; Anna Ayres; Stephen J Kent; Joseph Sasadeusz; Sharon R Lewin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Characteristics of hepatitis C virus infection in HIV-infected people.

Authors:  C L Cooper; A D Badley; J B Angel
Journal:  Can J Infect Dis       Date:  2001-05

Review 9.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

10.  Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.

Authors:  Ighovwerha Ofotokun; Sarah E Smithson; Chengxing Lu; Kirk A Easley; Jeffrey L Lennox
Journal:  Am J Med Sci       Date:  2007-11       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.